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HPLCAbstract Carboxyterfenadine, a primary metabolite of terfenadine, a second generation antihista-
minic compound was introduced in therapy as a successor of terfenadine due to its cardiac arrhyth-
mia. There are number of drug interactions of fexofenadine with erythromycin, ketoconazole and
alike reported in the literature. In this paper, fexofenadine antacid interaction has been studied in
presence of sodium bicarbonate, megaldrate, calcium carbonate, magnesium carbonate, aluminum
hydroxide, magnesium hydroxide, magnesium trisilicate, simethicone (dimethylpolysiloxane) and
calcium hydroxide by UV–Vis spectrophotometer and high performance liquid chromatography
(HPLC). These in vitro fexofenadine–antacid interactions were carried out in simulated gastric
and intestinal juices and in buffer of pH 7.4 (simulating blood pH) on BP 2005 dissolution appa-
ratus. The results show non-concordant availability of fexofenadine envisaged due to formation
of unstable charge transfer complexes.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Fexofenadine, (±)-4-[1-hydroxy-4-[4-(hydroxydiphenylmeth-
yl)-1-piperidinyl]-butyl]-a,a-dimethylbenzeneacetic acid
hydrochloride, a primary oxidative metabolite of terfenadine
(Amon et al., 2000) is a second generation antihistamine. Itdoes not cross the blood–brain barrier and therefore does
not cause drowsiness. The most common adverse reactions in-
clude headache, dizziness, drowsiness, nausea, sleepiness, ner-
vousness, nightmares and frequent coughing (Tanizaki et al.,
2012; Haberfeld, 2010; Dinnendahl and Fricke, 2010) and
rarely cause hypersensitivity (Lee et al., 2011; Mathias et al.,
2012). It is well-tolerated and a promising probe for studies
of membrane transporter function (Flynn et al., 2011).
There are number of reported drug interactions of fexofen-
adine. It forms a solid state complex with b-cyclodextrin (Sap-
kal et al., 2010). Erythromycin and ketoconazole increase the
plasma levels of fexofenadine two- to three-fold without inﬂu-
encing the QT interval. The reason for this effect is not well
understood and could be caused by increased absorption or re-
840 H. Shehnaz et al.duced gastrointestinal or biliary secretion (Klopp, 2010; Ka-
math et al., 2005). It is not to be taken with fruit juice because
fruit juice could decrease absorption of the drug (Kamath
et al., 2005; Dresser and Bailey, 2003; Kamath et al., 2004).
Grapefruit juice can signiﬁcantly reduce the plasma concentra-
tion of fexofenadine. Antacids containing aluminum or mag-
nesium reduce the absorption of fexofenadine (Walther and
Holtermu¨ller, 1983).
Antacids neutralize acids leading to several products result-
ing in insoluble compounds. The neutralization rates and
capacities are also affected in presence of organic acids, pep-
tone polypeptides (Flynn et al., 2011; Sapkal et al., 2010).
The rate of absorption of drug can also be increased or de-
creased due to the interference of antacid by changing the ion-
ization state, solubility or pH factors (Romankiewi, 1976;
Maton and Burton, 1999; Arayne and Sultana, 1993). Multiva-
lent cations also interfere with the availability of ciproﬂoxacin
(Arayne et al., 2005). The interactions with H2-receptor antag-
onist reveal that they are not temperature dependant, but pH
dependant and occur more frequently in more acidic or basic
medium (Shahnaz et al., 2012a; 2012b).
In present paper the in vitro release of fexofenadine in pres-
ence of sodium bicarbonate, magaldrate, calcium carbonate,
magnesium carbonate, aluminum hydroxide, magnesium
hydroxide, magnesium trisilicate, simethicone (dim-
ethylpolysiloxane) and calcium hydroxide has been studied in
simulated gastric and intestinal juices and in buffer of pH
7.4 simulating blood pH at 37 C and the drug availability in
each case was monitored by UV–Visible spectrophotometer
and high performance liquid chromatography (RP-HPLC).
2. Experimental
2.1. Materials
Fexofenadine was gifted by Aventis Pharma (Pvt.) Limited,
Pakistan. Antacids were sodium bicarbonate, megaldrate, cal-
cium carbonate, magnesium carbonate, aluminum hydroxide,
magnesium hydroxide, magnesium trisilicate, simethicone
and calcium hydroxide and all are of pharmaceutical grade
passed through 170 Mesh Screen 0.088 mm.
2.2. Reagents
Methanol, hydrochloric acid, potassium chloride, ammonia
solution 33%, deionized water. All the reagents used were of
analytical grade or puriﬁed in the laboratory according to
standard procedures (Arayne et al., 2007). Potassium chloride
recrystallized before use in water and methanol. All glasswares
were washed with chromic acid followed by deionized water,
which was freshly prepared in laboratory and used throughout
the work.
2.3. Equipments
The dissolution equipment was fabricated as described earlier
(Arayne et al., 2007). The rotation speed of the basket assem-
bly was ﬁxed at 1000 ± 0.5 rpm throughout the experiment.
The dissolution assembly was immersed in a water bath at
37 ± 0.1 C. A double beam UV/visible spectrophotometer
(Shimadzu) model UV1601 coupled with a P IV computerloaded with UVPC version 3.9 software was used for analysis
of drug samples. The quartz cells of 10 mm path length were
used. The HPLC system (Shimadzu, Japan) comprised of
LC-10 AT VP pump, Rheodyne manual injector ﬁtted with a
20 lL loop, Purospher STAR RP-18 end capped (5 lm,
25 · 0.46 cm) column and SPD-10 A VP UV–VIS detector (Ja-
pan) were utilized. Chromatographic system was integrated via
Shimadzu model CBM-102 to P IV computer. Shimadzu
CLASS-GC software (version 2) was used for data acquisition
and mathematical calculations. Bath sonicator (LC-30 H,
Elma, Germany); Analytical balance (PL303 Mettler Toledo,
USA), Filtration assembly (Sartorius, Goettingen, Germany),
Filter papers 0.45 lm, 13 mm (Sartorius, Hannover, Ger-
many); Sartorius Minisart RC 4 Syringe ﬁlters 0.45 lm, What-
man 41 ﬁlter paper circles of diameter 125 mm (Whatman,
Maidstone, England) were also used.
3. Results and Discussion
3.1. Adsorption studies
Interactions with antacids were carried out in simulated gastric
juice, simulated intestinal juice and in buffer of pH 7.4 at
37 C. Antacids used were sodium bicarbonate, calcium
hydroxide, calcium carbonate, magnesium carbonate, alumi-
num hydroxide, magnesium hydroxide, magnesium trisilicate,
magaldrate and simethicone. Analysis was conducted by add-
ing 10 mL (1 mmol) fexofenadine solution to the dissolution
medium at zero time and after 15 min before collecting the ﬁrst
sample 2 g of each antacid was added to the dissolution med-
ium separately in every individual set of experiment. Aliquots
withdrawn were assayed for fexofenadine contents and graphs
were plotted between drug concentration and time which
showed drug status during and at the end of the experiments.
3.2. Fexofenadine antacids interaction by UV spectrophotometer
Antacids are drugs taken orally to neutralize hydrochloric acid
secreted by the stomach. The temporary rise in the pH of gas-
tric content will reduce the pain of peptic ulcer (Fujishima
et al., 2008; Tarnawski et al., 2013), in this age of fast food,
overeating, and busy schedules, many people frequently com-
plain of heartburn or indigestion. Meal timings are rarely con-
sistent, so meal planning appears out of the question.
Gastroesophageal reﬂux disease is a common disorder that af-
fects every population (Frost-Rud, 1999).
The in vitro availability studies of fexofenadine hydrochlo-
ride in presence of antacids were individually carried out in
simulated gastric juice, simulated intestinal juice and in buffer
of pH 7.4 at 37 C. Antacids used are sodium bicarbonate, cal-
cium hydroxide, calcium carbonate, magnesium carbonate,
aluminum hydroxide, magnesium hydroxide, magnesium trisil-
icate, magaldrate and simethicone. The reaction was started by
adding 10 ml of 1 mMole fexofenadine to the dissolution med-
ium at zero time while after 15 min before collecting the sam-
ple, 2 gm of each antacid was added to the dissolution medium
separately in each individual set of experiment. The results are
mentioned in Tables 1–3. Graph has been plotted for the ﬁrst
order dissolution rate constant of drug concentration versus
time in each set of experiment in presence or absence of
antacids.
Table 1 Concentration of fexofenadine (%) in the presence of antacids at different time intervals in simulated gastric juice at 37 C.
S. No. Sample 0 15 30 45 60 75 90 105 120 135 150 165 180
1 Fexofenadine 0.406 0.211 0.197 0.198 0.187 0.182 0.202 0.185 0.183 0.189 0.187 0.192 0.196
2 FX+ Sodium bicarbonate 0.448 0.225 0.304 0.353 0.323 0.401 0.342 0.338 0.277 0.281 0.396 0.28 0.263
3 FX+ Calcium hydroxide 0.282 0.284 0.236 0.252 0.238 0.224 0.248 0.236 0.245 0.241 0.23 0.238 0.235
4 FX+ Calcium carbonate 0.618 0.54 0.359 0.276 0.40 0.905 0.414 0.319 0.555 0.535 0.223 0.358 0.22
5 FX+Magnesium carbonate 0.494 0.35 0.3 0.246 0.23 0.218 0.225 0.246 0.225 0.22 0.224 0.214 0.229
6 FX+ Aluminum hydroxide 0.278 0.367 0.251 0.24 0.183 0.352 0.269 0.229 0.214 0.193 0.197 0.206 0.2
7 FX+Magnesium hydroxide 0.373 0.338 0.306 0.268 0.251 0.24 0.245 0.249 0.258 0.253 0.224 0.214 0.229
8 FX+Magnesium tri silicate 0.221 0.398 0.261 0.256 0.27 0.236 0.23 0.228 0.229 0.223 0.231 0.218 0.213
9 FX+ Simethicone 0.363 0.469 0.268 0.228 0.223 0.218 0.221 0.248 0.27 0.255 0.226 0.23 0.208
10 FX+Megaldrate 0.203 0.409 0.373 0.308 0.373 0.351 0.37 0.386 0.382 0.388 0.387 0.383 0.394
Table 2 Concentration of fexofenadine (%) in the presence of antacids at different time intervals in buffer pH 7.4 at 37 C.
S. No. Sample 0 15 30 45 60 75 90 105 120 135 150 165 180
1 Fexofenadine 0.167 0.166 0.163 0.164 0.163 0.168 0.168 0.176 0.18 0.174 0.18 0.18 0.198
2 FX+ Sodium bicarbonate 0.142 0.504 0.39 0.326 0.338 0.31 0.308 0.295 0.31 0.3 0.29 0.3 0.295
3 FX+ Calcium hydroxide 0.198 0.351 0.256 0.227 0.226 0.219 0.223 0.229 0.229 0.244 0.247 0.267 0.251
4 FX+ Calcium carbonate 0.165 0.321 0.211 0.203 0.189 0.19 0.198 0.188 0.198 0.194 0.189 0.203 0.205
5 FX+Magnesium carbonate 0.400 0.434 0.339 0.307 0.304 0.303 0.295 0.3 0.298 0.298 0.297 0.31 0.2987
6 FX+ Aluminum hydroxide 0.605 0.512 0.406 0.378 0.382 0.377 0.374 0.389 0.363 0.368 0.00 0.362 0.379
7 FX+Magnesium hydroxide 0.201 0.425 0.251 0.265 0.241 0.23 0.219 0.228 0.276 0.252 0.247 0.223 0.256
8 FX+Magnesium tri silicate 0.21 0.433 0.27 0.242 0.239 0.239 0.232 0.231 0.23 0.248 0.248 0.247 0.247
9 FX+ Simethicone 0.859 0.388 0.285 0.257 0.228 0.229 0.22 0.228 0.224 0.222 0.216 0.214 0.222
10 FX+Megaldrate 0.231 0.343 0.215 0.197 0.2 0.197 0.214 0.193 0.195 0.198 0.206 0.203 0.192
Table 3 Concentration of fexofenadine (%) in the presence of antacids at different time intervals in stimulated intestinal juice at
37 C.
S. No. Sample 0 15 30 45 60 75 90 105 120 135 150 165 180
1 Fexofenadine 0.071 0.106 0.103 0.101 0.107 0.103 0.101 0.099 0.102 0.095 0.098 0.103 0.122
2 FX+ Sodium bicarbonate 0.66 0.607 0.724 0.702 0.678 0.644 0.66 0.717 0.622 0.62 0.549 0.73 0.535
3 FX+ Calcium hydroxide 0.4 0.871 0.62 0.547 0.522 0.499 0.523 0.503 0.492 0.486 0.478 0.477 0.469
4 FX+ Calcium carbonate 1.307 0.638 0.397 0.349 0.324 0.314 0.31 0.306 0.338 0.307 0.388 0.404 0.36
5 FX+Magnesium carbonate 0.072 0.428 0.222 0.437 0.547 0.266 0.21 0.243 0.164 0.151 0.253 0.156 0.154
6 FX+ Aluminum hydroxide 0.139 0.591 0.503 0.481 0.469 0.459 0.453 0.436 0.438 0.461 0.422 0.436 0.413
7 FX+Magnesium hydroxide 0.239 0.66 0.367 0.306 0.308 0.293 0.329 0.329 0.353 0.299 0.284 0.318 0.301
8 FX+Magnesium tri silicate 0.404 0.604 0.487 0.5 0.565 0.616 0.678 0.671 0.667 0.667 0.656 0.655 0.659
9 FX+ Simethicone 0.251 0.635 0.407 0.326 0.358 0.304 0.293 0.282 0.273 0.256 0.276 0.268 0.27
10 FX+Magaldrate 0.617 0.669 0.484 0.433 0.4 0.388 0.391 0.378 0.378 0.386 0.378 0.393 0.388
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clinical relevance and mechanism of action of antacids on fexo-
fenadine in simulated gastric juice at 37 C. 10 ml of 1 mmole
of fexofenadine is added and after 5 min 2 g sodium bicarbon-
ate is added at 15 min; the availability of fexofenadine is
shown in Tables 1–3. The % availability of fexofenadine in
simulated gastric juice with sodium bicarbonate, calcium car-
bonate and magnesium carbonate was greater than fexofena-
dine (0.406–0.494%) Figs. 1–5. While in presence of calcium
hydroxide, aluminum hydroxide, magnesium hydroxide, mag-
nesiumtrisilicate, simethicone and magaldrate the % avail-
ability of fexofenadine decreased (Table 1).
The in vitro availability of fexofenadine with antacids in
buffer of pH 7.4 was performed by the same procedure inwhich % availability of fexofenadine was 0.198%, respectively.
When antacids were added to fexofenadine, % availability
with calcium hydroxide was same 0.198% but with sodium
carbonate, calcium carbonate, aluminum hydroxide, magne-
sium carbonate, magnesium hydroxide, magnesiumtrisilicate,
simethicone and magaldrate the % availability of fexofena-
dine increased as shown in Table 2.
The in vitro availability of fexofenadine with antacids in
simulated intestinal juice was performed by the same proce-
dure in which % availability of fexofenadine with magnesium
carbonate decreased. The % availability of fexofenadine was
0.072 %. Moreover, this study signiﬁes that with sodium car-
bonate, calcium carbonate, calcium hydroxide, aluminum
hydroxide, magnesium hydroxide, magnesium trisilicate,
Availability of fexofenadine in presence of Aluminium Hydroxide
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Figure 1 Availability of fexofenadine in presence of aluminum hydroxide at 37 C.
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at 37oC
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Figure 2 Availability of fexofenadine in presence of calciumcarbonate at 37 C.
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was increased as shown in Table 3.
The in vitro availability of fexofenadine was found to be
markedly retarded in the presence of few antacids while in
most of the cases the drug contents appeared to be more than
the drug added which reﬂects the possible complexation of
these di- and tri-valent metal cations with fexofenadine. More-
over, these studies indicated that fexofenadine was powerfully
adsorbed on calcium hydroxide, aluminum hydroxide, magne-
sium hydroxide, magnesium trisilicate, simethicone and mag-
aldrate in simulated gastric juice, with calcium hydroxide in
simulated intestinal juice and there was no adsorption of fexo-
fenadine with calcium hydroxide in buffer of pH 7.4,
respectively.
3.3. Fexofenadine antacids interaction by HPLC
10 mL fexofenadine solution and 0.2 g antacid were taken in a
conical ﬂask and the ﬂask was shaken for 2 h at 37 C, after-ward the aliquots were ﬁltered through a 0.45 lm Millipore
ﬁlter paper. The mobile phase was prepared by mixing metha-
nol and 6.8 g monobasic potassium phosphate in 1000-ml
water and pH was adjusted to 7.4 with potassium hydroxide.
The composition was methanol: phosphate buffer, 35:65 (v/
v), respectively. The injection volume was 10 lL and the run
time was 5.0 min. The mobile phase was ﬁltered using a 0.45-
lm membrane ﬁlter (Millipore) and degassed in ultrasonic
bath. The mobile phase ﬂow rate was 1.0 ml min1. Samples
were injected through a 20 lL loop at ambient and the reten-
tion time for fexofenadine was 3.65–3.75 min (Arayne et al.,
2009). Peak area and percentage of fexofenadine recovered
have been discussed in Table 4. Peak areas were in contrast
with standard fexofenadine solutions to evaluate the degree
of interaction of fexofenadine with antacids. The chromato-
grams of adsorption studies carried out at HPLC have been
shown in Figs. 7 and 8. In simulated gastric juice the percent-
age recovery of the fexofenadine increased in case of sodium
bicarbonate (110.3%), magnesium carbonate (121.7%) and
Availability of fexofenadine in presence of Magnesiumtrisilicate
at 37oC
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Figure 5 Availability of fexofenadine in presence of magnesiumtrisilicate at 37 C.
Availability of fexofenadine in presence of Simethicone
at 37oC
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Figure 4 Availability of fexofenadine in presence of simethicone at 37 C.
Availability of fexofenadine in presence of Sodiumbicarbonate
at 37oC
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Figure 3 Availability of fexofenadine in presence of sodiumbicarbonate at 37 C.
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Figure 7 Fexofenadine–antacid adsorption studies in simulated
gastric juice by HPLC.
Figure 8 Fexofenadine–antacid adsorption studies in simulated
intestinal juice by HPLC.
Figure 6 Possible binding sites at fexofenadine.
Table 4 Adsorption studies (%) of antacids with fexofenadine analyzed by reversed-phase HPLC.
S. no Sample Simulated gastric juice Simulated intestinal juice
Peak area % Recovery Peak area % Recovery
1 Fexofenadine 20761 100.0 19236 100
2 FX+ Sodium bicarbonate 22909.4 110.3 25103.8 115.03
3 FX+Megaldrate 13068.2 69.5 22952.4 109.29
4 FX+ Calcium carbonate 32498.1 107 26865.9 110
5 FX+Magnesium carbonate 16595.6 121.7 8050.77 43.65
6 FX+ Aluminum hydroxide 11683 68.5 20783.6 115
7 FX+Magnesium hydroxide 27856.6 91.9 21482.9 104
8 FX+Magnesium tri silicate 12301.5 54.4 19207.5 110.38
9 FX+ Simethicone 30101.7 89.4 18535.3 122
10 FX+ Calcium hydroxide 11610.3 50.0 20266.9 106.01
844 H. Shehnaz et al.in all other antacids it decreased while in simulated intestinal
juice the percent recovery of fexofenadine increased in case
of sodium bicarbonate (115.03%), megaldrate (109.29%),
Magnesium trisilicate (110.38%) and calcium hydroxide
(106.01%). Fexofenadine (Fig. 6) has piperidine nitrogen and
at tertiary carbon it has a carboxylic group and that is why
it subsists as a zwitter ion in aqueous media at physiological
pH. These two possible sites are responsible for complex for-
mation and fexofenadine–antacid interaction takes place.
4. Conclusion
The fexofenadine antacid interaction has been carried out on
both UV spectrophotometer and HPLC and the results reveal
that the percentage availability of fexofenadine has been wide-
ranging in case of various antacids and the piperidine ring, a
carboxylic group and two hydroxyl groups illustrate that it
has a signiﬁcant afﬁnity to form charge transfer complexes.
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